JCEM: Relationship between obstructive sleep apnea and metabolic abnormalities in patients with hypertrophomyopathy

Metabolic abnormalities are associated with long-term heart mortality in patients with hypertrophomyopathy (HCM).
obstructive sleep apnea (OSA) is a risk factor for metabolic abnormalities in the general population, the association between metabolic abnormalities in OSA and HCM patients is not clear.
, a research paper was published in Journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, to explore the relationship between metabolic dysfunction in patients with OSA and HCM.
the study included a total of 587 HCM patients who received sleep assessments at out-of-hospital hospitals, and collected clinical characteristics, polysogram examination and metabolic measurements of the subjects.
344 patients had OSA (58.6%), and OSA patients were older, more male, and more clinically combined.
with the increase in the severity of OSA, body mass index, blood pressure, peri-heart blood sugar and triglycerides all increased (all P-lt;0.001), and HDL cholesterol decreased (P-0.046).
in the multivariable analysis, moderate to severe OSA and Log (AHI (apnea low-breathing index) and obesity (OR 2.42; 95% CI is .48-3.95); OR is 1.60; 95% CI is .1. 31- 1.95), hypertension (OR 1.99; 95% CI is 1.42-3.26) and OR is 1.31; 95% CI is .08-1.60) and high triglycerides (OR) 1.71; 95% CI is .05-2.78) and OR is 1.24; 95% CI is independently related to .02-1.51), but is associated with high blood sugar on an empty stomach (OR 0.88; 95% CI is . . . 0.50-1.52 and OR are 1.02; 95% CI is .82-1.28) and reduced HDL cholesterol (OR is 1.30; 95% CI is .83-2.04) Not related to OR 1.06; 95% CI is .89-1.27).
, the severity of OSA is associated with certain metabolic abnormalities and clinical trials are needed to determine whether OSA therapy can improve metabolic abnormalities and long-term outcomes in HCM patients.